Blueprint Medicines rises on FDA submission for bone-marrow disease drug

Blueprint Medicines

23/11/2022 17:06

** Shares of drug developer Blueprint Medicines  BPMC.O  up
4.2% at $45.3
    ** Co says it has submitted a marketing application to
expand the label for its bone marrow disorder to include adults
with slow-progressing Systemic Mastocytosis  urn:newsml:reuters.com:*:nPn1Y9wc4a
    ** According to the National Institutes of Health, Systemic
Mastocytosis is a bone-marrow disorder in which white blood
cells accumulate in internal tissues and organs, and can cause
organ failure 
    ** Last year, co's treatment, AYVAKIT, was approved by the
FDA for rreatment of adults with advanced Systemic Mastocytosis
    ** Stock fell 57.7% YTD
 (Reporting by Nandhini Srinivasan in Bengaluru)
 ((nandhini.srinivasan@thomsonreuters.com))